Company intelligence / Profile preview

Novilla Pharmaceuticals

Cambridge, Massachusetts, United Statesnovilla.net ↗

Ownership: Private
Development stage: Commercial

Overview

Novilla Pharmaceuticals is developing a patented transdermal/topical drug delivery platform aimed at providing effective pain relief without the risks associated with traditional opioid medications. Their approach seeks to minimize systemic exposure and addiction risk by delivering drugs directly to the site of action. As an early-stage company founded in 2019, they are advancing preclinical or possibly early clinical programs targeting pain management.

Therapeutic areas: Neurology
Modalities: Small moleculeTransdermal technology
Industry: Biotech

Drug pipeline

1 asset

NOV-1776

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed.

Beyond the preview

Go deeper on Novilla Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novilla Pharmaceuticals.

Explore the full profile